chartexchange

ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights

GlobeNewswire Inc. | Nov 12, 2026 4:10 PM EST

WINSTON-SALEM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2026 and provided business highlights and upcoming milestones.

Read original article